Literature DB >> 8735260

Decoquinate and the control of experimental ovine toxoplasmosis.

D Buxton1, J Brebner, S Wright, S W Maley, K M Thomson, K Millard.   

Abstract

Decoquinate was tested for its ability to reduce the effect of experimentally induced toxoplasmosis in pregnant ewes. Sheep were given decoquinate in their feed daily at either 2 mg or 1 mg/kg bodyweight from 10 days before an oral challenge with Toxoplasma gondii oocysts at 90 days of gestation, until lambing. Feeding decoquinate at the higher rate caused a delay in the onset of the febrile response to infection, reduced the overall severity of the fever and delayed the production of antibodies to the parasite. This treatment also reduced the placental damage caused by the parasite, lengthened the mean gestation period and increased the number and weight of live lambs, in comparison with ewes not fed decoquinate but challenged with T gondii oocysts. The treatment with 1 mg of decoquinate had smaller effects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8735260     DOI: 10.1136/vr.138.18.434

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  10 in total

1.  Presumptive Toxoplasma gondii abortion in a sheep.

Authors:  Judith Weissmann
Journal:  Can Vet J       Date:  2003-04       Impact factor: 1.008

2.  Reduction of the abortion rate due to Toxoplasma in 3 goat herds following administration of sulfadimidine.

Authors:  Nektarios D Giadinis; Shawkat Q Lafi; Evi Ioannidou; Elias Papadopoulos; Konstantinos Terpsidis; George Karanikolas; Evanthia J Petridou; Christos Brozos; Harilaos Karatzias
Journal:  Can Vet J       Date:  2013-11       Impact factor: 1.008

3.  Treatment with Bumped Kinase Inhibitor 1294 Is Safe and Leads to Significant Protection against Abortion and Vertical Transmission in Sheep Experimentally Infected with Toxoplasma gondii during Pregnancy.

Authors:  Roberto Sánchez-Sánchez; Ignacio Ferre; Michela Re; Juan José Ramos; Javier Regidor-Cerrillo; Manuel Pizarro Díaz; Marta González-Huecas; Enrique Tabanera; Julio Benavides; Andrew Hemphill; Matthew A Hulverson; Lynn K Barrett; Ryan Choi; Grant R Whitman; Kayode K Ojo; Wesley C Van Voorhis; Luis Miguel Ortega-Mora
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

4.  Structure-activity relationships of Toxoplasma gondii cytochrome bc1 inhibitors.

Authors:  P Holland Alday; Aaron Nilsen; J Stone Doggett
Journal:  Expert Opin Drug Discov       Date:  2022-08-08       Impact factor: 7.050

5.  Preparation of Decoquinate Solid Dispersion by Hot-Melt Extrusion as an Oral Dosage Form Targeting Liver-Stage Plasmodium Infection.

Authors:  Hongxing Wang; Yinzhou Fan; Li Qin; Zhipeng Cheng; Xueqing Chen; Sumei Zeng; Shuanghong Liang; Ying Tong; Zhu Tao; Yucheng Liu; Xiaorong Liu; Xiaohui Ning; Peiquan Chen; Siting Zhao; Xiaoping Chen
Journal:  Antimicrob Agents Chemother       Date:  2022-06-06       Impact factor: 5.938

6.  Experimental ovine toxoplasmosis: influence of the gestational stage on the clinical course, lesion development and parasite distribution.

Authors:  Pablo Castaño; Miguel Fuertes; Javier Regidor-Cerrillo; Ignacio Ferre; Miguel Fernández; M Carmen Ferreras; Javier Moreno-Gonzalo; Camino González-Lanza; Juana Pereira-Bueno; Frank Katzer; Luis Miguel Ortega-Mora; Valentín Pérez; Julio Benavides
Journal:  Vet Res       Date:  2016-03-16       Impact factor: 3.683

7.  Safety and efficacy of the bumped kinase inhibitor BKI-1553 in pregnant sheep experimentally infected with Neospora caninum tachyzoites.

Authors:  Roberto Sánchez-Sánchez; Ignacio Ferre; Michela Re; Patricia Vázquez; Luis Miguel Ferrer; Javier Blanco-Murcia; Javier Regidor-Cerrillo; Manuel Pizarro Díaz; Marta González-Huecas; Enrique Tabanera; Paula García-Lunar; Julio Benavides; Pablo Castaño; Andrew Hemphill; Matthew A Hulverson; Grant R Whitman; Kasey L Rivas; Ryan Choi; Kayode K Ojo; Lynn K Barrett; Wesley C Van Voorhis; Luis Miguel Ortega-Mora
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-03-02       Impact factor: 4.077

8.  Assessment of the Activity of Decoquinate and Its Quinoline-O-Carbamate Derivatives against Toxoplasma gondii In Vitro and in Pregnant Mice Infected with T. gondii Oocysts.

Authors:  Jessica Ramseier; Dennis Imhof; Nicoleta Anghel; Kai Hänggeli; Richard M Beteck; Vreni Balmer; Luis-Miguel Ortega-Mora; Roberto Sanchez-Sanchez; Ignacio Ferre; Richard K Haynes; Andrew Hemphill
Journal:  Molecules       Date:  2021-10-22       Impact factor: 4.411

Review 9.  Chemical and Pharmacological Properties of Decoquinate: A Review of Its Pharmaceutical Potential and Future Perspectives.

Authors:  Tainá Santos Souza; Diogo Rodrigo Magalhães Moreira; Henrique Rodrigues Marcelino
Journal:  Pharmaceutics       Date:  2022-06-30       Impact factor: 6.525

10.  Seroconversion to Brucella spp. and Toxoplasma gondii in Sheep and Goats in Dohuk Province, Iraq and Its Association with Pregnancy Loss.

Authors:  Ali Al Hamada; Ihab Habib; Mieghan Bruce; Anne Barnes; Ian D Robertson
Journal:  Animals (Basel)       Date:  2021-03-16       Impact factor: 2.752

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.